About this Journal Submit a Manuscript Table of Contents
International Journal of Inflammation
Volume 2011 (2011), Article ID 231926, 6 pages
http://dx.doi.org/10.4061/2011/231926
Review Article

Definition of Nonresponse to Analgesic Treatment of Arthritic Pain: An Analytical Literature Review of the Smallest Detectable Difference, the Minimal Detectable Change, and the Minimal Clinically Important Difference on the Pain Visual Analog Scale

1Scribco Pharmaceutical Writing, P.O. Box 1525, Blue Bell, PA 19422, USA
2Departments of Global Health Outcomes, Epidemiology, and Clinical Development, Merck & Co., Inc., One Merck Drive, Whitehouse Station, NJ 08889, USA

Received 25 January 2011; Accepted 8 March 2011

Academic Editor: Bernhard Rintelen

Copyright © 2011 Melissa E. Stauffer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Our objective was to develop a working definition of nonresponse to analgesic treatment of arthritis, focusing on the measurement of pain on the 0–100 mm pain visual analog scale (VAS). We reviewed the literature to assess the smallest detectable difference (SDD), the minimal detectable change (MDC), and the minimal clinically important difference (MCID). The SDD for improvement reported in three studies of rheumatoid arthritis was 18.6, 19.0, and 20.0. The median MDC was 25.4 for 7 studies of osteoarthritis and 5 studies of rheumatoid arthritis (calculated for a reliability coefficient of 0.85). The MCID increased with increasing baseline pain score. For baseline VAS tertiles defined by scores of 30–49, 50–65, and >65, the MCID for improvement was, respectively, 7–11 units, 19–27 units, and 29–37 units. Nonresponse can thus be defined in terms of the MDC for low baseline pain scores and in terms of the MCID for high baseline scores.